Combination of anti-LAG-3 antibodies and anti-PD-1 antibodies to treat tumors
US10081681B2 · kind B2 · utility
10Cited by
39References
18Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 18, 2014 |
| Grant date | Sep 25, 2018 |
| Priority date | — |
| Expiry date | Apr 30, 2035 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2317/94
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided are methods for clinical treatment of tumors (e.g., advanced solid tumors) using an anti-LAG-3 antibody in combination with an anti-PD-1 antibody.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.